The invention relates to a composition comprising buprenorphine and a µ opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = / EC 50 c max BUP c max ANTAGONIST / IC 50 .